- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05030298
Preoperativ strålkirurgi för behandling av höggradigt gliom, NeoGliom-studien
Preoperativ strålkirurgi vid höggradigt gliom: en klinisk fas I/IIA-prövning: NeoGliom-studien
This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pre-operative radiosurgery may improve the odds of brain tumor control and reduce treatment-related side effects.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To evaluate the feasibility, safety and maximum tolerated dose (MTD) of preoperative radiosurgery in the treatment of patients with biopsy-proven high-grade glioma prior to conventional therapy.
SECONDARY OBJECTIVES:
I. Acute clinical toxicity profile using Common Terminology Criteria for Adverse Events (CTCAE) version 5 (defined as within 4 weeks of completion of postoperative radiotherapy.
II. Radiographic tumor control at 12 months following surgery (per Response Assessment in Neuro-Oncology [RANO] criteria).
III. Rate of pseudoprogression at first post radiation scan (RANO criteria). IV. Overall survival at 12 months following surgery.
CORRELATIVE RESEARCH OBJECTIVE:
I. Evaluation of the tumor repair pathways triggered by radiation, tumor vascular changes, tumor microenvironment immune profiling, cell cultures, and the creation of orthotopic xenograft models for future study.
OUTLINE: This is a dose-escalation study.
Patients undergo magnetic resonance imaging (MRI)-guided stereotactic biopsy. Within 14 days of registration, patients undergo either standard of care surgery or radiosurgery in 1 fraction. Within 14 days, patients who underwent radiosurgery then undergo surgery. Within 4-6 weeks, all patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without tumor treating fields (TTF) at the discretion of the treating neuro-oncologist. Additionally, patients undergo MRI and blood sample collection and optional biopsy throughout the study.
After completion of study treatment, patients are followed up every 2-3 months for 12 months and then every 3 months for up to 3 years after registration.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-post: mayocliniccancerstudies@mayo.edu
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Rekrytering
- Mayo Clinic in Arizona
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-post: mayocliniccancerstudies@mayo.edu
-
Huvudutredare:
- Sujay Vora, MD
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224-9980
- Rekrytering
- Mayo Clinic in Florida
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-post: mayocliniccancerstudies@mayo.edu
-
Huvudutredare:
- Daniel M. Trifiletti, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age >= 18 years
- Clear clinical and radiographic evidence of primary high grade glioma (HGG) as judged by the Mayo multidisciplinary neuro-oncology team (World Health Organization [WHO] grade III-IV, including glioblastoma) regardless of IDH and MGMT status
- Patients who underwent a previous biopsy confirming high grade glioma are eligible for enrollment
- Planned neurosurgical resection of tumor
- Judged to not be at risk of significant clinical risk (i.e. herniation) with radiation-induced edema prior to resection
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Negative pregnancy test done =< 14 days prior to registration, for women of childbearing potential only. Patients over 50 years of age who decline pregnancy testing are still eligible without a pregnancy test.
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide written informed consent
- Willing to receive adjuvant radiotherapy at enrolling institution at the time of registration
- Willing to provide tissue and/or blood samples for correlative research purposes
Exclusion Criteria:
-
Any of the following:
- Pregnant women
- Nursing women who are unwilling to cease during therapy
- Men or women of childbearing potential who are unwilling to employ adequate contraception
-
Prior history of cranial radiotherapy
-
Unwillingness to participate in study
-
Investigator discretion that enrollment on the study would pose undo harm or risk to the patient
-
Non-MRI compatible implanted medical device
-
Use of systemic anti-cancer therapy within the previous 3 months
-
Medical contraindication to craniotomy and tumor resection
-
Pathologic confirmation of grade I-II glioma, brain metastasis, or other brain tumor
- Note: Patients with a history of grade I-II glioma are eligible if they have only received surgery as treatment and now there is concern for transformation to grade III-IV tumor
-
Primary spinal cord glioma or primary brainstem glioma
-
Residual tumor of excessive volume or eloquent location per investigator discretion
-
Patients who are unwilling or unable to comply with study procedures
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (stereotactic biopsy, radiosurgery, surgery)
Patients undergo MRI-guided stereotactic biopsy. Within 14 days of registration, patients undergo either standard of care surgery or radiosurgery in 1 fraction. Within 14 days, patients who underwent radiosurgery then undergo surgery. Within 4-6 weeks, all patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist. Additionally, patients undergo MRI and blood sample collection and optional biopsy throughout the study. |
Undergo blood sample collection
Andra namn:
Undergo MRI
Andra namn:
Undergo radiation therapy
Andra namn:
Undergo surgery Undergo biopsy
Andra namn:
Undergo radiosurgery
Andra namn:
Undergo MRI-guided stereotactic biopsy Drug
Andra namn:
Undergo TTF
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients experiencing any acute grade 3 or greater unplanned adverse event
Tidsram: Up to 4 weeks postoperative radiotherapy
|
Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. The toxicity rate will be estimated using a binomial estimator and a one-sided 95% confidence interval (CI) of the rate will be computed with normal approximation. |
Up to 4 weeks postoperative radiotherapy
|
|
Acute clinical toxicity
Tidsram: Up to 4 weeks postoperative radiotherapy
|
Assessed per CTCAE v5.0. The maximum grade for each type of acute adverse events will be recorded for each patient. Data will be summarized as frequencies and relative frequencies by treatment arm. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Rates will be compared between arms using chi-squared tests. |
Up to 4 weeks postoperative radiotherapy
|
|
Maximum tolerated dose (MTD) of preoperative radiosurgery
Tidsram: Up to 4 weeks postoperative radiotherapy
|
After the trial is completed, the MTD will be based on isotonic regression. The dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate will be selected as the MTD. If there are ties, the higher dose level will be selected when the isotonic estimate is lower than the target toxicity rate; and the lower dose level will be selected when the isotonic estimate is greater than or equal to the target toxicity rate. |
Up to 4 weeks postoperative radiotherapy
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Radiographic tumor control
Tidsram: At 12 months post-surgery
|
Assessed per Response Assessment in Neuro-Oncology (RANO) criteria. The cumulative incidence of radiographic tumor recurrence will be estimated using a competing risks method (Gooley et al.). The competing risks will be death. |
At 12 months post-surgery
|
|
Rate of pseudoprogression
Tidsram: At first post radiation scan
|
Assessed per RANO criteria. Data will be summarized as frequencies and relative frequencies overall and by treatment dose. Additionally, the relationship of the pseudoprogression(s) to the study treatment will be taken into consideration. |
At first post radiation scan
|
|
Overall survival
Tidsram: At 12 months post-surgery
|
Overall survival (OS) is defined as the time from study enrollment to death by any cause. Will be estimated with a Kaplan-Meier estimator and curve for patients treated with preoperative radiosurgery. Estimates will be given for specific time points along with 95% CIs. |
At 12 months post-surgery
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Tumor tissue evaluation of tumor changes
Tidsram: Up to 14 days Post-radiosurgery
|
Any excess tissue recovered from the surgical specimen (after standard of care pathologic evaluation) will undergo a series of advanced testing, potentially including but not limited to evaluation of the tumor repair pathways triggered by radiation, tumor vascular changes, tumor microenvironment immune profiling, cell cultures, and the creation of orthotopic xenograft models for future study. Analysis will be completed outside the scope of this protocol. |
Up to 14 days Post-radiosurgery
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Daniel M. Trifiletti, MD, Mayo Clinic
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Gliom
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Undersökningstekniker
- Terapeutik
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kirurgiska ingrepp, operativ
- Azoler
- Cytologiska tekniker
- Cytodiagnos
- Fysiska fenomen
- Dacarbazin
- Triazenes
- Imidazoler
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Stereotaxiska tekniker
- Neurokirurgiska förfaranden
- Temozolomid
- Strålbehandling
- Strålning
- Biopsi
- Provhantering
- Magnetresonansspektroskopi
- Strålkirurgi
Andra studie-ID-nummer
- MC210710
- 20-013209 (Annan identifierare: Mayo Clinic Institutional Review Board)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .